3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
9
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Interventions
selpercatinib
2
Trastuzumab
2
Paclitaxel
2
sodium thiosulfate
1
pazopanib
1
glutathione pegylated liposomal doxorubicin
1
fluoroacetic acid
1
elacestrant
1
durvalumab
1
carboxyamido-triazole
1
abemaciclib
1
Temozolomide
1
Taxes
1
Surveys and Questionnaires
1
RAD1901
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
MLN 8237
1
Levofloxacin
1
Lapatinib
1
Immunotherapy
1
Immunoenzyme Techniques
1
Genetic Testing
1
Genetic Counseling
1
Gemcitabine
1
Drug Therapy
1
D-methadone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
RAD1901
×
Breast
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled